UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 50

Sortiert nach

Statistical methods in recent HIV noninferiority trials: reanalysis of 11 trials

PloS one, 2011-09, Vol.6 (9), p.e22871-e22871

2011

Volltextzugriff (PDF)

Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients

PloS one, 2012-05, Vol.7 (5), p.e36673-e36673

2012

Volltextzugriff (PDF)

Antiretroviral therapy as a risk factor for chronic kidney disease: Results from traditional regression modeling and causal approach in a large observational study

PloS one, 2017-12, Vol.12 (12), p.e0187517-e0187517

2017

Volltextzugriff (PDF)

SARS-CoV-2 Neutralizing Responses in Various Populations, at the Time of SARS-CoV-2 Variant Virus Emergence: Evaluation of Two Surrogate Neutralization Assays in Front of Whole Virus Neutralization Test

Life (Basel, Switzerland), 2022-12, Vol.12 (12), p.2064

2022

Volltextzugriff (PDF)

Choice of effect measure in HIV randomized trials

AIDS (London), 2015-09, Vol.29 (15), p.2057-2060

Flandre, Philippe

2015

Volltextzugriff (PDF)

Choice of treatment-effect measures when noninferiority margins originally defined in absolute difference translated into relative difference influenced the results of clinical trials

Journal of clinical epidemiology, 2018-04, Vol.96, p.63-72

2018

Volltextzugriff (PDF)

Polymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimen

PloS one, 2011-09, Vol.6 (9), p.e24798

2011

Volltextzugriff (PDF)

Similar evolution of cellular HIV-1 DNA level in darunavir/ritonavir monotherapy versus triple therapy in MONOI-ANRS136 trial over 96 weeks

PloS one, 2012-07, Vol.7 (7), p.e41390-e41390

2012

Volltextzugriff (PDF)

Some current issues in the design of HIV noninferiority trials

AIDS (London), 2014-08, Vol.28 (13), p.1921-1929

FLANDRE, Philippe

2014

Volltextzugriff (PDF)

Design of HIV noninferiority trials: where are we going?

AIDS (London), 2013-02, Vol.27 (4), p.653-657

FLANDRE, Philippe

2013

Volltextzugriff (PDF)

HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and Response to Maraviroc

PloS one, 2015-06, Vol.10 (6), p.e0127816-e0127816

2015

Volltextzugriff (PDF)

Scoring methods for building genotypic scores: an application to didanosine resistance in a large derivation set

PloS one, 2013-03, Vol.8 (3), p.e59014

2013

Volltextzugriff (PDF)

A polymorphism at position 400 in the connection subdomain of HIV-1 reverse transcriptase affects sensitivity to NNRTIs and RNaseH activity

PloS one, 2013-10, Vol.8 (10), p.e74078-e74078

2013

Volltextzugriff (PDF)

Description of the L76V resistance protease mutation in HIV-1 B and "non-B" subtypes

PloS one, 2013-01, Vol.8 (1), p.e54381-e54381

2013

Volltextzugriff (PDF)

Fat tissue distribution changes in HIV-infected patients treated with lopinavir/ritonavir. Results of the MONARK trial

Current HIV research, 2011-01, Vol.9 (1), p.31

2011

Volltextzugriff (PDF)

The Short-Term and Long-Term Hazard Ratio Model: Parameterization Inconsistency

The American statistician, 2021-10, Vol.75 (4), p.376-382

2021

Volltextzugriff (PDF)

The Use of the Restricted Mean Survival Time as a Treatment Measure in HIV/AIDS Clinical Trial: Reanalysis of the ACTG A5257 Trial

Journal of acquired immune deficiency syndromes (1999), 2019-05, Vol.81 (1), p.44

2019

Volltextzugriff (PDF)

Tenofovir and changes in renal function

AIDS (London), 2010-02, Vol.24 (4), p.619-620

Flandre, Philippe

2010

Volltextzugriff (PDF)

Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136

AIDS (London), 2010-09, Vol.24 (15), p.2365-2374

2010

Volltextzugriff (PDF)

High rate of early HEV seroconversion after liver transplantation among cirrhotic patients: Should we test for it?

The Journal of infection, 2023-07, Vol.87 (1), p.88-90

2023

Volltextzugriff (PDF)

Addition of Etravirine Does Not Enhance the Initial Decline of HIV-1 RNA in Treatment-Experienced Patients Receiving Raltegravir

Journal of acquired immune deficiency syndromes (1999), 2017-08, Vol.75 (4), p.448

2017

Volltextzugriff (PDF)

Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma on a 2002―2011 survey

AIDS (London), 2012-05, Vol.26 (8), p.971-975

2012

Volltextzugriff (PDF)

Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients

AIDS (London), 2008-01, Vol.22 (3), p.385-393

2008

Volltextzugriff (PDF)

Clinical presentation of Covid-19 in health care workers from a French University Hospital

The Journal of infection, 2020-09, Vol.81 (3), p.e61-e63

2020

Volltextzugriff (PDF)

Does first-line antiretroviral regimen impact risk for chronic kidney disease whatever the risk group?

AIDS (London), 2016-06, Vol.30 (9), p.1433-1438

2016

Volltextzugriff (PDF)

1 – 25 von 50

Suche als RSS-Feed

Aktive Filter

SpracheFranzösisch

KollektionIngenta

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(50)
Mit Volltextzugriff
(41)

Publikationsform

Artikel
(50)

Sprache

Englisch
(50)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Statistical methods in recent HIV noninferiority trials: reanalysis of 11 trials

Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients

Antiretroviral therapy as a risk factor for chronic kidney disease: Results from traditional regression modeling and causal approach in a large observational study

SARS-CoV-2 Neutralizing Responses in Various Populations, at the Time of SARS-CoV-2 Variant Virus Emergence: Evaluation of Two Surrogate Neutralization Assays in Front of Whole Virus Neutralization Test

Choice of effect measure in HIV randomized trials

Choice of treatment-effect measures when noninferiority margins originally defined in absolute difference translated into relative difference influenced the results of clinical trials

Polymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimen

Similar evolution of cellular HIV-1 DNA level in darunavir/ritonavir monotherapy versus triple therapy in MONOI-ANRS136 trial over 96 weeks

Some current issues in the design of HIV noninferiority trials

Design of HIV noninferiority trials: where are we going?

HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and Response to Maraviroc

Scoring methods for building genotypic scores: an application to didanosine resistance in a large derivation set

A polymorphism at position 400 in the connection subdomain of HIV-1 reverse transcriptase affects sensitivity to NNRTIs and RNaseH activity

Description of the L76V resistance protease mutation in HIV-1 B and "non-B" subtypes

Fat tissue distribution changes in HIV-infected patients treated with lopinavir/ritonavir. Results of the MONARK trial

The Short-Term and Long-Term Hazard Ratio Model: Parameterization Inconsistency

The Use of the Restricted Mean Survival Time as a Treatment Measure in HIV/AIDS Clinical Trial: Reanalysis of the ACTG A5257 Trial

Tenofovir and changes in renal function

Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136

High rate of early HEV seroconversion after liver transplantation among cirrhotic patients: Should we test for it?

Addition of Etravirine Does Not Enhance the Initial Decline of HIV-1 RNA in Treatment-Experienced Patients Receiving Raltegravir

Detection of HIV-1 RNA in seminal plasma samples from treated patients with undetectable HIV-1 RNA in blood plasma on a 2002―2011 survey

Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients

Clinical presentation of Covid-19 in health care workers from a French University Hospital

Does first-line antiretroviral regimen impact risk for chronic kidney disease whatever the risk group?

Aktive Filter

Suchergebnisse filtern